Class Action Filed Against Mereo BioPharma Group plc (MREO) - April 6, 2026 Deadline to Join - Contact The Gross Law Firm

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging that the company made misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints [1][1][1] Summary by Relevant Sections Allegations - The complaint claims that Mereo BioPharma provided overly positive statements to investors while concealing material adverse facts about the Phase 3 ORBIT and COSMIC programs [1][1] - Neither the ORBIT nor the COSMIC studies achieved statistical significance in reducing the annualized clinical fracture rate compared to placebo or bisphosphonate control groups [1][1] Financial Impact - Following the announcement on December 29, 2025, that the studies did not meet their primary endpoints, Mereo's American Depositary Shares (ADS) price plummeted from $2.31 per share on December 26, 2025, to $0.29 per share on December 29, 2025, marking a decline of over 87.7% [1][1][1] Class Action Details - The class period for the lawsuit is defined as June 5, 2023, to December 26, 2025, with a deadline of April 6, 2026, for shareholders to register for participation [1][1] - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [1][1]